Factor VIII therapy for hemophilia A: current and future issues
Aledort, Louis ; Ljung, Rolf LU
; Mann, Kenneth
and Pipe, Steven
(2014)
In Expert Review of Hematology
7(3).
p.373-385
- Abstract
- Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4544984
- author
- Aledort, Louis
; Ljung, Rolf
LU
; Mann, Kenneth
and Pipe, Steven
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- factor concentrate, FVIII, gene therapy, genetics, hemophilia A, immunogenicity, longer, acting FVIII, prophylaxis
- in
- Expert Review of Hematology
- volume
- 7
- issue
- 3
- pages
- 373 - 385
- publisher
- Informa Healthcare
- external identifiers
-
- wos:000337290300008
- scopus:84900839290
- pmid:24717090
- ISSN
- 1747-4086
- DOI
- 10.1586/17474086.2014.899896
- language
- English
- LU publication?
- yes
- id
- dd7ca7dc-2542-45a2-9926-9f88df5f56c8 (old id 4544984)
- date added to LUP
- 2016-04-01 09:56:49
- date last changed
- 2022-04-12 00:24:40
@article{dd7ca7dc-2542-45a2-9926-9f88df5f56c8,
abstract = {{Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.}},
author = {{Aledort, Louis and Ljung, Rolf and Mann, Kenneth and Pipe, Steven}},
issn = {{1747-4086}},
keywords = {{factor concentrate; FVIII; gene therapy; genetics; hemophilia A; immunogenicity; longer; acting FVIII; prophylaxis}},
language = {{eng}},
number = {{3}},
pages = {{373--385}},
publisher = {{Informa Healthcare}},
series = {{Expert Review of Hematology}},
title = {{Factor VIII therapy for hemophilia A: current and future issues}},
url = {{http://dx.doi.org/10.1586/17474086.2014.899896}},
doi = {{10.1586/17474086.2014.899896}},
volume = {{7}},
year = {{2014}},
}